[Sponsored] FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
The post Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options appeared first on MedCity News.
